Company Monitoring Page for Amgen

job ratings (see below graph) for Amgen

latest headlines for company on cafepharma

Amgen prices bone builder Evenity at $21,900/year to compete on convenience, not cost
Endpoints
Tue, 04/16/19 - 09:50 am
Tags:
Amgen, osteoporosis, Evenity, drug pricing
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
EP Vantage
Sat, 04/13/19 - 12:23 pm
Tags:
Amgen, Enbrel, CymaBay, NASH, Erelzi, seladelpar, Genfit
FDA approves Evenity for osteoporosis
BioCentury
Tue, 04/9/19 - 07:03 pm
Tags:
FDA, Evenity, romosozumab, Amgen, UCB Pharma, osteoporosis
With biosims closing in, Amgen CEO Bradway scored 10% raise to $18.6M in 2018
Fierce Pharma
Tue, 04/9/19 - 06:54 pm
Tags:
Amgen, Bob Bradway, executive pay
Scotland backs Aimovig for migraine after NICE says no
Pharmaforum
Tue, 04/9/19 - 08:20 am
Tags:
Scotland, NICE, migraines, Aimovig, Amgen, Novartis
The top 15 pharma companies by 2018 revenue
Fierce Pharma
Mon, 04/8/19 - 11:30 pm
Tags:
JNJ, Roche, Pfizer, Novartis, Merck, GSK, Sanofi, AbbVie, Bayer, Eli Lilly, Amgen, Bristol-Myers Squibb, Gilead Sciences, Teva Pharmaceutical, AstraZeneca
Coherus' Neulasta biosimilar surprises with strong early uptake
Biopharma Dive
Mon, 04/8/19 - 05:44 pm
Tags:
Coherus Biosciences, Neulasta, biosimilars, Udenyca, Amgen
Lawsuit over migraine deal could be good for Amgen, analysts say
Marketwatch
Sat, 04/6/19 - 02:09 pm
Tags:
Novartis, Amgen, migraines, Aimovig
Amgen and Novartis file dueling lawsuits over their deal to market a migraine drug
Stat
Thu, 04/4/19 - 11:22 pm
Tags:
Novartis, Amgen, Aimovig, migraines
Novartis sues Amgen over migraine treatment Aimovig
Yahoo/Reuters
Thu, 04/4/19 - 12:04 pm
Tags:
Novartis, Amgen, Aimovig, migraines
Sandoz resubmission puts Amgen's Neulasta at further risk of competition
Biopharma Dive
Wed, 04/3/19 - 09:31 pm
Tags:
FDA, Novartis, biosimilars, Sandoz, Amgen, Neulasta
3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop
Motley Fool
Sat, 03/30/19 - 12:44 pm
Tags:
Alzheimer's disease, Biogen, aducanumab, Otsuka, Axsome Therapeutics, Amgen, Novartis, Avanir, AVP-786, AXS-05, AMG520
Amgen, Servier heart failure drug clears trial hurdle
PM Live
Thu, 03/21/19 - 06:50 pm
Tags:
Amgen, Servier, heart failure, Omecamtiv Mecarbil, clinical trials
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Investors Business Daily
Sat, 03/16/19 - 12:21 pm
Tags:
Amgen, Repatha, clinical trials
Amgen's top-selling Enbrel in balance as key court ruling nears
Biopharma Dive
Wed, 03/13/19 - 04:32 pm
Tags:
Amgen, patents, Enbrel, biosimilars
3 Big Pharmas Trying to Pop the Rebate Bubble
Motley Fool
Wed, 03/6/19 - 10:06 am
Tags:
drug pricing, drug rebates, Eli Lilly, Amgen, Gilead Sciences
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
Tue, 03/5/19 - 09:40 am
Tags:
market exclusivity, patents, Rituxan, Lyrica, Herceptin, Avastin, Epclusa, Harvoni, Pfizer, Roche, Gilead Sciences, Amgen, GSK, Allergan, Individor
A Closer Look At The Drug Rebate Proposal
Forbes
Sat, 03/2/19 - 12:57 pm
Tags:
drug pricing, drug rebates, Donald Trump, healthcare reform, Amgen
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Pharmaceutical Business Review
Fri, 02/22/19 - 10:04 am
Tags:
Amgen, heart failure with reduced ejection fraction, Omecamtiv Mecarbil, Cytokinetics, Servier
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Mon, 02/11/19 - 12:23 pm
Tags:
Regeneron, Sanofi, Amgen, Praluent, Repatha, drug pricing, PCSK9 inhibitors

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.